menu search

BIIB / Lecanemab And Biogen's Path To Growth

Lecanemab And Biogen's Path To Growth
There is a critical upcoming catalyst for Biogen shareholders, a topline read out of data from the CLARITY-AD trial in Alzheimer's due in late September. One lesson from the Aduhelm fiasco is that data that clearly shows patients benefit from treatment is required for commercial success. Read More
Posted: Aug 22 2022, 03:05
Author Name: Seeking Alpha
Views: 110186

BIIB News  

Biogen Inc. (BIIB) Rises But Trails Market: What Investors Should Know

By Zacks Investment Research
October 30, 2023

Biogen Inc. (BIIB) Rises But Trails Market: What Investors Should Know

The latest trading day saw Biogen Inc. (BIIB) settling at $237.30, representing a +1.19% change from its previous close. more_horizontal

Biogen and Eisai's Revised Alzheimer's Drug Works, but Safety Questions Linger

By Barrons
October 26, 2023

Biogen and Eisai's Revised Alzheimer's Drug Works, but Safety Questions Linger

Wall Street analysts say Biogen and Eisai could secure Food and Drug Administration approval for their injected Alzheimer's drug. more_horizontal

Biogen and Eisai release new Alzheimer's drug data that may support wider uptake

By Market Watch
October 25, 2023

Biogen and Eisai release new Alzheimer's drug data that may support wider uptake

Biogen Inc. and Eisai Co. late Wednesday released new data on their Alzheimer's treatment Leqembi that may ultimately help bolster uptake of the drug. more_horizontal

Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market

By Zacks Investment Research
October 23, 2023

Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market

The latest trading day saw Biogen Inc. (BIIB) settling at $253.39, representing a -1.58% change from its previous close. more_horizontal

Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug

By Reuters
October 23, 2023

Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug

Swiss pharmaceutical company Roche has settled a patent lawsuit against U.S. biotech firm Biogen over its biosimilar version of Roche's blockbuster rh more_horizontal

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting

By GlobeNewsWire
October 19, 2023

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting

CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer's disease portfolio at the upc more_horizontal

Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know

By Zacks Investment Research
October 17, 2023

Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know

In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $267.43, denoting a -0.19% change from the preceding trading day. more_horizontal

Final Trades: WST, BIIB, SPY & MDT

By CNBC Television
October 11, 2023

Final Trades: WST, BIIB, SPY & MDT

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders. more_horizontal


Search within

Pages Search Results: